The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine

Phase 2

Completed

• Conditions: Influenza
• Interventions: Biological: split-virion, non-adjuvanted H1N1 vaccine of 45 μg; Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg; Biological: Placebo control; Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg

• Registration Number: NCT01336166
• Lead Sponsor: Shanghai Institute Of Biological Products

Brief Summary

The aim of this study is to investigate the long-term immunogenicity and safety of the inactivated split-virion vaccine after one immunization.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2011-04-07
• Study First Submitted QC: 2011-04-14
• Study First Posted: 2011-04-15
• Primary Completion: 2011-07
• Study Completion: 2011-07
• Status Verified: 2015-10
• Last Update Submitted: 2018-09-08
• Last Update Posted: 2018-09-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 480

Inclusion Criteria

1. Different age groups from 18 to 60 years, with normal intelligence and health. Volunteers (or their guardians) are well informed of the situation and sign the consent
2. Vaccination recipients qualified for this product have been inquired about medical history and clinically proven to be healthy
3. Requests of clinical research program can be obeyed
4. No other protective product is inoculated in last week
5. Axillary temperature below 37 degrees Celsius

Exclusion Criteria

1. Volunteers in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
2. Volunteers allergic to ingredient of vaccine composition (can be checked from vaccination history), especially to egg
3. History of progressive or severe neurologic disorder
4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
5. Known or suspected impairment/alteration of immune function, for example receiving immunosuppressive therapy or receiving blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation
6. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
7. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
8. History of thyroidectomy or thyroid disease that required medication within the past 12 months
9. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
10. Guillain-Barre Syndrome
11. Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
12. Any other vaccines or immunoglobulin preparation within 1 weeks prior to enrollment
13. Axillary temperature ≥ 38.0 degrees Celsius within 3 days of intended study vaccination
14. Any conditions may influence the evaluation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
split-virion, non-adjuvanted vaccine of 45 μg	split-virion, non-adjuvanted H1N1 vaccine of 45 μg	split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
split-virion, non-adjuvanted vaccine of 15 μg	split-virion, non-adjuvanted H1N1 vaccine of 15 μg	split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
Placebo control	Placebo control	Placebo control
split-virion, non-adjuvanted vaccine of 30 μg	split-virion, non-adjuvanted H1N1 vaccine of 30 μg	split-virion, non-adjuvanted H1N1 vaccine of 30 μg.

Primary Outcome Measures

Name	Time	Method
Hemagglutination inhibition antibody titer	Day 180

Secondary Outcome Measures

Name	Time	Method
occurrence of solicited local and systemic adverse events after vaccination	Days 0-42

Trial Locations

Locations (1)

Hunan Provincial Center of Disease Prevention and Control; 🇨🇳 Changsha, Hunan, China